Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation

References

• MartinPChadburnAChristosPOutcome of deferred initial therapy in mantle-cell lymphomaJ Clin Oncol2009271209121319188674
   PubMed Web of Science ®Google Scholar
• HiddemannWLongoDLCoiffierBLymphoma classification-the gap between biology and clinical management is closingBlood199688408540898943841
   PubMed Web of Science ®Google Scholar
• TiemannMSchraderCKlapperWHistopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL NetworkBr J Haematol2005131293816173960
   PubMed Web of Science ®Google Scholar
• RosenwaldAWrightGWiestnerAThe proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphomaCancer Cell2003318519712620412
   PubMed Web of Science ®Google Scholar
• Rubio-MoscardoFClimentJSiebertRMantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcomeBlood20051054445445415718413
   PubMed Web of Science ®Google Scholar
• SchaffelRHedvatCVTeruya-FeldsteinJPrognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphomaAnn Oncol201021113313920019090
   PubMed Web of Science ®Google Scholar
• HsiEDJungSHLaiRKi67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science studyLeuk Lymphoma2008492081209019021050
   PubMed Web of Science ®Google Scholar
• KlapperWHosterEDetermannOKi-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL NetworkJ Hematop2009210311119669190
   PubMedGoogle Scholar
• HosterEDreylingMKlapperWGisselbrechtCA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood200811155856517962512
   PubMed Web of Science ®Google Scholar
• ShahJJFayadLRomagueraJMantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVADBlood2008112258318779406
   PubMed Web of Science ®Google Scholar
• GeislerCHKolstadALaurellAThe Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive firstline immunochemotherapy and autologous stem cell transplantation (ASCT)Blood20101151530153320032504
   PubMed Web of Science ®Google Scholar
• HerrmannAHosterEZwingersTImprovement of overall survival in advanced stage mantle cell lymphomaJ Clin Oncol20092751151819075279
   PubMed Web of Science ®Google Scholar
• RomagueraJEFayadLRodriguezMAHigh rate of durable remissions after treatment of newly diagnosed aggressive mantlecell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJ Clin Oncol2005237013702316145068
   PubMed Web of Science ®Google Scholar
• HowardOMGribbenJGNeubergDSRituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survivalJ Clin Oncol2002201288129411870171
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMHosterEImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol2005231984199215668467
   PubMed Web of Science ®Google Scholar
• SchulzHBohliusJSkoetzNChemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphomaCochrane Database Syst Rev200717CD00380517943799
   PubMed Web of Science ®Google Scholar
• SchulzHBohliusJFTrelleSImmunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisJ Natl Cancer Inst20079970671417470738
   PubMed Web of Science ®Google Scholar
• MeusersPEngelhardMBartelsHMulticentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosisHematol Oncol198973653802670728
   PubMed Web of Science ®Google Scholar
• NickenigCDreylingMHosterECombined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study GroupCancer20061071014102216878325
   PubMed Web of Science ®Google Scholar
• SmithMRChenHGordonLPhase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group study E1499J Clin Oncol2007247503
   Web of Science ®Google Scholar
• DreylingMLenzGHosterEEarly consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood20051052677268415591112
   PubMed Web of Science ®Google Scholar
• PottCSchraderCGeskSQuantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaBlood20061072271227816332971
   PubMed Web of Science ®Google Scholar
• VandenbergheERuiz de ElviraCLoberizaFROutcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant RegistriesBr J Haematol200312079380012614212
   PubMed Web of Science ®Google Scholar
• KolstadALaurellAAndersenNS90y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma – Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)Blood200911493219643993
   PubMed Web of Science ®Google Scholar
• KhouriIFRomagueraJKantarjianHHyper-CVAD and highdose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphomaJ Clin Oncol199816380338099850025
   PubMed Web of Science ®Google Scholar
• VoseJMBiermanPJWeisenburgerDDAutologous hematopoietic stem cell transplantation for mantle cell lymphomaBiol Blood Marrow Trans20006640645
   PubMed Web of Science ®Google Scholar
• GopalAKRajendranJGPetersdorfSHHigh-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphomaBlood2002993158316211964278
   PubMed Web of Science ®Google Scholar
• GeislerCHKolstadALaurellALong-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood20081122687269318625886
   PubMed Web of Science ®Google Scholar
• ChopraRGoldstoneAHPearceRAutologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a casecontrolled analysis of the European Bone Marrow Transplant Group Registry dataJ Clin Oncol199210169016951403052
   PubMed Web of Science ®Google Scholar
• RatanatharathornVUbertiJKaranesCProspective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphomaBlood199484105010558049425
   PubMed Web of Science ®Google Scholar
• VerdonckLFDekkerAWLokhorstHMPetersenEJNieuwenhuisHKAllogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphomaBlood199790420142059354692
   PubMed Web of Science ®Google Scholar
• KhouriIFSalibaRMGiraltSANonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortalityBlood2001983595359911739162
   PubMed Web of Science ®Google Scholar
• KhouriIFMcLaughlinPSalibaRMEight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabBlood20081115530553618411419
   PubMed Web of Science ®Google Scholar
• FaulknerRDCraddockCByrneJLBEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patientsBlood200410342843412969983
   PubMed Web of Science ®Google Scholar
• KhouriIFAlbitarMSalibaRMLow-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokineticsBone Marrow Trans200433833837
   PubMed Web of Science ®Google Scholar
• KhouriIFLeeMSRomagueraJAllogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancyAnn Oncol1999101293129910631455
   PubMed Web of Science ®Google Scholar
• BerdejaJGJonesRJZahurakMLAllogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphomaBiol Blood Marrow Trans20017561567
   Web of Science ®Google Scholar
• RifkindJMolleePMessnerHALiptonJHAllogeneic stem cell transplantation for mantle cell lymphoma – does it deserve a better look?Leuk Lymphoma20054621722315621804
   PubMed Web of Science ®Google Scholar
• GantiAKBiermanPJLynchJCBociekRGVoseJMArmitageJOHematopoietic stem cell transplantation in mantle cell lymphomaAnn Oncol20051661862415781489
   PubMed Web of Science ®Google Scholar
• AdkinsDBrownRGoodnoughLTKhouryHPopovicWDiPersioJTreatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantationBone Marrow Trans1998219799
   PubMed Web of Science ®Google Scholar
• BondanzaAValtolinaVMagnaniZSuicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytesBlood20061071828183616293601
   PubMed Web of Science ®Google Scholar
• RobinsonSPGoldstoneAHMackinnonSChemoresistant or aggressive lymphoma predicts for a poor outcome following reducedintensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow TransplantationBlood20021004310431612393626
   PubMed Web of Science ®Google Scholar
• KhouriIFLeeMSSalibaRMNonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphomaJ Clin Oncol2003214407441214645431
   PubMed Web of Science ®Google Scholar
• MorrisEThomsonKCraddockCOutcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphomaBlood20041043865387115304395
   PubMed Web of Science ®Google Scholar
• MarisMBSandmaierBMStorerBEAllogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphomaBlood20041043535354215304387
   PubMed Web of Science ®Google Scholar
• SorrorMLStorerBSandmaierBMSustained graft-versus-lymphoma effect among patients (pts) with Mantle Cell Lymphoma (MCL) given nonmyeloablative allogeneic Hematopoietic Cell Transplantation (HCT)Blood20081122147
   Google Scholar
• TamCSBassettRLedesmaCMature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphomaBlood20091134144415219168784
   PubMed Web of Science ®Google Scholar
• RobinsonSPSuredaACanalsCSrIdentification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma. An analysis from the Lymphoma Working Party of the EBMTBlood200811245718650457
   PubMed Web of Science ®Google Scholar
• PasquiniMCWangZCurrent use and outcome of hematopoietic stem cell transplantation: part II- CIBMTR summary slidesCIBMTR Newsletter20091459
   Google Scholar